Drugs / Burfiralimab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06306339 | Mar 2024 → May 2025 | rheumatoid arthritis | ImmuneMed, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05808335 | Jan 2022 → Mar 2024 | chronic hepatitis B virus infection | ImmuneMed, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Burfiralimab | “A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)” NCT05808335 ↗ |
| Known as | hzVSF-v13 | “A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)” NCT05808335 ↗ |
| Modality | Monoclonal antibody | “Humanized monoclonal antibody.” NCT06306339 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT06306339 ↗ |